AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20946162
Drug: Late rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late rehabilitation (sildenafil citrate twice weekly starting at 6 months postoperatively)
Trial: 11419823
Drug: Standard U.S.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard U.S. 13C‐urea breath test (125 mg of 13C‐urea, pudding test meal, breath sample taken 30 min after ingestion)
Trial: 11419823
Drug: Simplified UBT‐Lite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simplified UBT‐Lite (75 mg of 13C‐urea, 2.5-g citric acid test meal, breath sample taken 15 min after ingestion)
Trial: 12267108
Drug: ML Cu250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ML Cu250
Trial: 31553254
Drug: Low-dose EGF
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose EGF
Trial: 31553254
Drug: High-dose EGF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose EGF
Trial: 31553254
Drug: Low-dose EGF
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose EGF vs High-dose EGF
Trial: 28059565
Drug: message reception
FDA approved: no
EMA approved: no
PMDA approved: no
Description: message reception and expression (treatment group)
Trial: 17690485
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of hop water extract (HWE)
Trial: 15694055
Drug: Intramuscular etofenamate
RxNorm normalized name: etofenamate
DrugBank: Etofenamate (DB08984)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular etofenamate (1 g/day)
Trial: 15694055
Drug: Intramuscular diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular diclofenac (75 mg/day)
Trial: 2923424
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion of morphine sulphate
Trial: 2923424
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous infusion of ketamine hydrochloride
Trial: 2923424
Drug: Combined continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined continuous subcutaneous infusion of morphine sulphate and ketamine hydrochloride
Trial: 2923424
Drug: Intramuscular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular morphine sulphate
Trial: 31494365
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine 1.0 mg/kg
Trial: 31494365
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine 0.5 mg/kg
Trial: 31494365
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine 0.1 mg/kg
Trial: 22967997
Drug: Platinum throughout
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum throughout treatment
Trial: 10705078
Drug: Insulin (euglycemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (euglycemic hyperinsulinemic clamping)
Trial: 10705078
Drug: Insulin (stopped
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (stopped after clamping)
Trial: 29458931
Drug: Horticultural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horticultural therapy program (10 sessions, once a week from April 2017 to June 2017)
Trial: 26660337
Drug: Low-intensity wheelchair
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity wheelchair training (30-40% heart rate reserve, twice a week, for 30 min per session)
Trial: 25592012
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 800 μg/d
Trial: 14974365
Drug: Reduced dose
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced dose of CyA and daclizumab (group A)
Trial: 14974365
Drug: Normal dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal dose of CyA without daclizumab (group B)
Trial: 9363911
Drug: Azelastine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine (4 mg/day)
Trial: 8489205
Drug: Lazabemide 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lazabemide 400 mg/day
Trial: 29203092
Drug: Pemafibrate 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemafibrate 0.2 mg/d
Trial: 29203092
Drug: Pemafibrate 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemafibrate 0.4 mg/d
Trial: 29203092
Drug: Fenofibrate 106.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 106.6 mg/d
Trial: 27486235
Drug: DHEA (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (800 mg)
Trial: 27486235
Drug: DHEA (1,600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA (1,600 mg)
Trial: 18272323
Drug: Atypical antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotic medication
Trial: 15863811
Drug: Conventional antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antipsychotic medication
Trial: 1291926
Drug: Nimesulide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide (1 tablet b.i.d. for 10 days)
Trial: 1291926
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (1 tablet b.i.d. for 10 days)
Trial: 3908879
Drug: Regular exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular exercise (endurance training), thrice weekly for one year
Trial: 24148608
Drug: Cardioembolic stroke
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardioembolic stroke (patients unwilling or unable to take oral anticoagulants)
Trial: 18518865
Drug: Oxygen flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen flow rate of 5 l.min(‐1)
Trial: 18518865
Drug: Oxygen flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen flow rate of 10 l.min(‐1)
Trial: 18518865
Drug: Oxygen flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen flow rate of 15 l.min(‐1)
Trial: 12735671
Drug: Montelukast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (10 mg) plus intravenous prednisolone (1 mg/kg)
Trial: 12735671
Drug: Intravenous prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous prednisolone (1 mg/kg)
Trial: 1662978
Drug: Alkalinized local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkalinized local anaesthetic mixture (0.5% bupivacaine 10 ml, 2% lignocaine 10 ml with adrenaline 1 in 200,000, plus 8.4% sodium bicarbonate 2 ml)
Trial: 1662978
Drug: Plain local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain local anaesthetic mixture (0.5% bupivacaine 10 ml and 2% lignocaine 10 ml with adrenaline 1 in 200,000)
Trial: 6172942
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with 0.05% retinoic acid without occlusion
Trial: 25285468
Drug: Caffeinated nitric
RxNorm normalized name: Nitric Acid
DrugBank: Nitric acid (DB15995)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated nitric oxide lozenge (70mg)
Trial: 24342530
Drug: ω‐3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 PUFA supplementation (EPA: 1.67 g EPA + 0.16 g DHA/d; n = 12)
Trial: 24342530
Drug: ω‐3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 PUFA supplementation (DHA: 1.55 g DHA + 0.40 g EPA/d; n = 12)
Trial: 24342530
Drug: ω‐6 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐6 PUFA linoleic acid (LA: 2.2 g/d; n = 9)
Trial: 20024700
Drug: Polyalkylimide gel
RxNorm normalized name: polyacrylamide (10000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyalkylimide gel (PAIG) injections at week 0 and 6
Trial: 12368394
Drug: (n-3) fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (n-3) fatty acids (1.5 g daily)
Trial: 10099032
Drug: Tiagabine (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiagabine (titrated from 8 to 48 mg/d)
Trial: 7862924
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum and patch
Trial: 2764865
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (16 two-hour sessions over 4 consecutive days)
Trial: 2764865
Drug: Spaced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spaced treatment (two two-hour sessions per week for eight weeks)
Trial: 2764865
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment formats
Trial: 324830
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Anafranil and Pertofran
Trial: 27939035
Drug: Early introduction
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early introduction of heated egg powder (50 mg/day from 6 to 9 months, 250 mg/day from 9 to 12 months)
Trial: 25806626
Drug: Action Planning
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Action Planning and Coping Planning strategies for medication adherence
Trial: 24112026
Drug: milatuzumab 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: milatuzumab 1.5 mg/kg, 4.0 mg/kg, 8.0 mg/kg, or 16.0 mg/kg administered twice weekly x 4
Trial: 11295628
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein intervention in men with PSA failure (PSA 0.1 to 2.0 ng/mL), treatment duration of 8 months.
Trial: 7981558
Drug: G‐ORS (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐ORS (standard glucose ORS)
Trial: 29357333
Drug: 10 mL,
RxNorm normalized name: syringe, ENFit 10 mL, sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL, 40 µg/mL of O₃‐O₂
Trial: 29357333
Drug: 10 mL,
RxNorm normalized name: syringe, ENFit 10 mL, sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL, 30 µg/mL of O₃‐O₂
Trial: 20421817
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (high-dose single-drug ifosfamide)
Trial: 18387719
Drug: RTS,S/AS02 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS02 vaccine on a 0, 1, and 3 month schedule
Trial: 18387719
Drug: RTS,S/AS02 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS02 vaccine on a 0, 7, and 28 day schedule
Trial: 12025912
Drug: Oxerutins (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxerutins (2 g/day for grade I CVI, 3 g/day for grade II CVI in the first 2 weeks; then 1 g/day for grade I CVI, 2 g/day for grade II CVI in the following 2 weeks)
Trial: 10428191
Drug: Risperidone (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (up to 2.0 mg/d) for 6 weeks
Trial: 1974399
Drug: Loratadine 40
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loratadine 40 mg
Trial: 31325466
Drug: Silver diamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver diamine fluoride (SDF) solution
Trial: 27593794
Drug: Fluoroscopy-guided caudal
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoroscopy-guided caudal epidural steroid injection
Trial: 24315625
Drug: Adjuvant anthracycline-based
RxNorm normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant anthracycline-based chemotherapy combined with taxanes
Trial: 17545758
Drug: Chemotherapy (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (Group 1)
Trial: 17545758
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy (Group 2)
Trial: 9856712
Drug: Regularly administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regularly administered intramuscular injections of morphine
Trial: 7832132
Drug: Intracoronary nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary nicorandil 1.5 mg in the left coronary artery
Trial: 7832132
Drug: Intracoronary nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary nicorandil 1.0 mg in the right coronary artery
Trial: 7832132
Drug: Intracoronary nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary nicorandil (various doses)
Trial: 7192456
Drug: Propranolol (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (120 to 360 mg daily, mean 198 +/- 80 mg) for 3.5 weeks to 7 months (averaging 3 months)
Trial: 30559343
Drug: Papacarie gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papacarie gel (caries removal with the chemical‐mechanical method)
Trial: 26054549
Drug: Reimbursement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reimbursement of up to 50 US dollars for purchased vegetables (treatment group, n=69)
Trial: 24365793
Drug: Oral NAC
RxNorm normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral NAC + i.v. saline
Trial: 19762222
Drug: Budesonide/formoterol maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol maintenance and reliever therapy (160/4.5 microg bid and as needed)
Trial: 19762222
Drug: Conventional best
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional best practice (CBP) (ICS or ICS/LABA+/−other agents at an approved dose plus as-needed SABA)
Trial: 11401008
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg EMD
Trial: 7989400
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose methylprednisolone; short course; dosage not specified; duration not specified.
Trial: 2658841
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day Tamoxifen
Trial: 2658841
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day Tamoxifen
Trial: 2658841
Drug: Dose escalation
RxNorm normalized name: PALFORZIA Initial Dose Escalation KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation to 40 mg/day after 20 mg/day
Trial: 4157346
Drug: One daily
RxNorm normalized name: One Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One daily intramuscular injection of 160 mg of gentamicin
Trial: 4157346
Drug: Three injections
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three injections daily (60 or 80 mg every 8 h)
Trial: 4157346
Drug: One daily
RxNorm normalized name: One Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One daily injection of gentamicin
Trial: 4157346
Drug: Three injections
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three injections daily
Trial: 29233097
Drug: DE-REACH intervention
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DE-REACH intervention (12 individual two-weekly sessions, 9 at home, 3 via telephone)
Trial: 23507477
Drug: HAM-RS2 (48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAM-RS2 (48 g dietary fibre from high-amylose maize type 2 resistant starch)
Trial: 19901711
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) - Enoxaparin sodium 40mg/d
Trial: 12498603
Drug: Infant orthopedics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant orthopedics (IO) treatment started within 2 weeks after birth until soft palate closure at 12 months of age.
Trial: 12498603
Drug: Non-infant orthopedics
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-infant orthopedics (non-IO) treatment with extra check-ups at 6 weeks and before and after lip repair and soft palate closure.
Trial: 17170610
Drug: Irbesartan/HCTZ combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan/HCTZ combination therapy (150 mg/12.5 mg, titrated to 300 mg/25 mg at week 1)
Trial: 17170610
Drug: Irbesartan monotherapy
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irbesartan monotherapy (150 mg, titrated to 300 mg at week 1)
Trial: 10516738
Drug: Irbesartan/HCTZ combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan/HCTZ combination therapy
Trial: 17170610
Drug: Irbesartan monotherapy
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irbesartan monotherapy
Trial: 10472868
Drug: Transdermal glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal glyceryl trinitrate (10- or 20-mg patch)
Trial: 10511361
Drug: Intravenous ritodrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ritodrine
Trial: 1902238
Drug: Erythromycin (333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (333 mg administered orally every 8 hr for 4 days)
Trial: 1902238
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (glyburide 5 mg administered on day 4 of each study period)
Trial: 28736381
Drug: Lisinopril treatment
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lisinopril treatment (experimental group)
Trial: 28736381
Drug: Captopril treatment
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril treatment (control group)
Trial: 24827134
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg once daily (after adjustment for baseline characteristics)
Trial: 24827134
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg once daily (exploratory analysis)
Trial: 19741011
Drug: MTX (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX (0.3 mg/kg/week, maximum of 20 mg/week, without escalating dose regimen)
Trial: 19741011
Drug: Initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial combination therapy with MTX and ADA (40 mg eow)
Trial: 19741011
Drug: MTX and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX and ADA combination therapy
Trial: 17971594
Drug: ATA +
RxNorm normalized name: Passiflora incarnata + valerian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATA + TOR (Atamestane 500 mg + Toremifene 60 mg)
Trial: 17971594
Drug: LET (Letrozole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LET (Letrozole 2.5 mg)
Trial: 11790868
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg daily) for 3 weeks
Trial: 11790868
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg daily) for 1 week
Trial: 10147334
Drug: Multizone treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multizone treatments
Trial: 10147334
Drug: Excimer laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excimer laser for compound myopic astigmatism
Trial: 23475691
Drug: tofacitinib 2
RxNorm normalized name: tofacitinib 22 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tofacitinib 2 mg twice daily
Trial: 22006202
Drug: tofacitinib 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tofacitinib 15 mg twice daily
Trial: 21349585
Drug: Combined medical
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined medical and psychological treatment (including antidepressants and health-visitor delivered non-directive counselling)
Trial: 17063220
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of oral citalopram
Trial: 12932601
Drug: Comparison group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison group (no atorvastatin)
Trial: 16517515
Drug: Traditional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional therapy (Control)
Trial: 8403176
Drug: Morphine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.1 mg.kg‐1 i.v.
Trial: 26845191
Drug: Axitinib (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib (two 5‐mg tablets daily on days 2‐19)